The investigation of insulin resistance markers and fasting triglyceride–glucose (TyG) indices in HER2-positive BC patients with BMs suggests that the TyG index could be used as a predictive biomarker at the time of diagnosis for the risk of time to BM, with a need for prospective studies confirming these data [81]. The gene discussed is ERBB2; the disease is breast cancer.